{"nctId":"NCT00600028","briefTitle":"Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide","startDateStruct":{"date":"2007-12"},"conditions":["Idiopathic Pulmonary Fibrosis","Cough"],"count":25,"armGroups":[{"label":"Experimental: Thalidomide, then placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: Placebo"]},{"label":"Experimental: Placebo, then Thalidomide","type":"EXPERIMENTAL","interventionNames":["Drug: Thalidomide","Drug: Placebo"]}],"interventions":[{"name":"Thalidomide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Idiopathic pulmonary fibrosis for \\>3 months \\<5 years\n* High resolution CT scan of chest consistent with IPF within the previous 12 months\n* FVC \\> 40% and \\< 90% predicted, TLC \\>40% \\<80%, DLCo \\>30% \\<90%\n* Chronic Cough - cough \\>8 weeks\n* Age \\>50\n* Non-child bearing potential\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Women of child bearing potential\n* Known etiology of lung fibrosis other than IPF\n* Significant respiratory toxin exposure\n* Collagen Vascular Disease\n* Use of narcotic anti-cough agent in last week\n* significant peripheral vascular disease or neuropathy\n* history of seizures\n* poorly controlled diabetes\n* allergy to thalidomide","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire.","description":"The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.\n\nCQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.\n\nCQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"13.7"},{"groupId":"OG001","value":"55.2","spread":"14.4"},{"groupId":"OG002","value":"61.6","spread":"11.9"},{"groupId":"OG003","value":"44.5","spread":"12.5"}]}]}]},{"type":"SECONDARY","title":"Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Visual Analog Scale of Cough and the St. George Respiratory Questionnaire.","description":"The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.\n\nSecondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.\n\nVisual analog scale of cough ranges from 0 to 100 (0 is considered the best).\n\nSt. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.\n\nSt. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"28.5"},{"groupId":"OG001","value":"65.9","spread":"23.3"},{"groupId":"OG002","value":"68","spread":"26.8"},{"groupId":"OG003","value":"17.8","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":"19.4"},{"groupId":"OG001","value":"54.7","spread":"16.9"},{"groupId":"OG002","value":"58.8","spread":"13.3"},{"groupId":"OG003","value":"40.7","spread":"9.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["constipation"]}}}